REDUCE-IT试验:二十碳五烯酸乙酯显著减少首次及总体心血管事件
本文为临床综述,阐述他汀治疗下LDL-C达标但甘油三酯升高者的残余ASCVD风险,并解读REDUCE-IT试验。该试验纳入8179例高危患者,每日4 g二十碳五烯酸乙酯显著减少主要终点、心血管死亡及首次与总体事件,提示降TG治疗新方向。
要点
- 他汀治疗后LDL-C达标而TG升高是重要残余ASCVD风险。
- REDUCE-IT中每日4 g二十碳五烯酸乙酯显著减少ASCVD事件。
- 高甘油三酯患者需在降LDL-C之外加强治疗。
核心结论
- 在他汀治疗基础上,二十碳五烯酸乙酯可显著减少高危高甘油三酯患者的ASCVD事件,包括心血管死亡及首次与总体终点事件。
研究设计与样本
- 临床综述,解读REDUCE-IT试验;该试验纳入8179例ASCVD高危且基线TG升高、LDL-C控制良好的患者。
主要发现
- REDUCE-IT显示每日4 g二十碳五烯酸乙酯显著改善主要终点及多个预设次要终点,包括心血管死亡、后续及总体主要和关键次要终点事件。
- 既往烟酸、贝特类、omega-3脂肪酸及膳食鱼油补充剂在他汀基础上未显示显著心血管事件减少。
关键数值与推荐
- REDUCE-IT基线TG中位数2.44 mmol/L(216.0 mg/dL),LDL-C中位数1.94 mmol/L(75.0 mg/dL),干预为每日4 g二十碳五烯酸乙酯。
临床怎么用
- 对他汀治疗后LDL-C达标但TG升高的高危患者,应考虑在降LDL-C之外加用二十碳五烯酸乙酯以进一步降低ASCVD风险。
局限性
- 本文为临床综述而非原始研究,未报告REDUCE-IT的完整安全性数据及亚组细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The aims of this clinical review are to: (i) highlight the importance of elevated baseline triglycerides (TG) in the setting of well-controlled low-density lipoprotein cholesterol (LDL-C) on statins as a major contributor to residual atherosclerotic cardiovascular disease (ASCVD) risk, particularly among patients with type 2 diabetes mellitus, metabolic syndrome, and obesity whose distinctive lipid phenotype cannot be optimally treated with LDL-C reduction therapy alone; (ii) describe the findings and clinical implications of the landmark REDUCE-IT trial in which ethyl eicosapentaenoic acid significantly improved ASCVD outcomes. While many genetic studies have shown that elevated TG are an independent causal factor for ASCVD, prior placebo-controlled trials using niacin, fibrates, omega-3 fatty acids, and dietary supplement fish oil preparations have failed to demonstrate significant CV event reduction when added to statin therapy. In contrast, the REDUCE-IT trial in 8179 participants showed convincingly that the administration of 4 g daily of icosapent ethyl (an ethyl ester of eicosapentaenoic acid) in patients at high risk for ASCVD with increased levels of baseline TG [median value, 2.44 mmol/L (216.0 mg/dL)] but well-controlled LDL-C [median value, 1.94 mmol/L (75.0 mg/dL)] reduced significantly incident events across both the trial primary endpoint and multiple prespecified secondary endpoints, including cardiovascular death, as well as both subsequent and total primary endpoint and key secondary endpoint events. Icosapent ethyl unequivocally contributed to ASCVD event reduction over and above statin therapy. The REDUCE-IT trial results should alter our approach to managing a growing population of hypertriglyceridaemic patients whose lipid phenotype requires more intensive treatment beyond LDL-C lowering alone.
引用
- Boden WE, Bhatt DL, Toth PP, et al. Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics. Eur Heart J. 2020. PMID: 31872245. doi:10.1093/eurheartj/ehz778
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。